The expression of Müllerian inhibiting substance/anti-Müllerian hormone type II receptor in myoma and adenomyosis
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objective We compared the expression levels of Müllerian inhibiting substance (MIS)/anti-Müllerian hormone type II receptor (AMHRII) in uterine myoma and adenomyosis to evaluate the possibility of using MIS/anti-Müllerian hormone (AMH) as a biological regulator or therapeutic agent in patients with uterine leiomyoma and adenomyosis. Methods We studied normal uterine myometrium, leiomyoma, endometrial tissue, and adenomyosis from 57 patients who underwent hysterectomy for uterine leiomyoma (22 cases) or adenomyosis (28 cases) and myomectomy for uterine myoma (7 cases). Immunohistochemical staining was used to confirm the MIS/AMHRII protein expression level in each tissue. Reverse transcription-polymerase chain reaction was performed to quantify MIS/AMHRII mRNA expression. Results The MIS/AMHRII protein was more strongly expressed in uterine myoma (frequency of MIS/AMHRII expressing cells: 51.95%±13.96%) and adenomyosis (64.65%±4.85%) tissues than that in the normal uterine myometrium (3.15%±1.69%) and endometrium (31.10%±7.19%). In the quantitative analysis of MIS/AMHRII mRNA expression, MIS/AMHRII mRNA expression levels in uterine myoma (mean density: 4.51±0.26) and adenomyosis (6.84±0.20) tissues were higher than that in normal uterine myometrial tissue (0.08±0.09) and endometrial tissue (1.63±0.06). Conclusion This study demonstrated that MIS/AMHRII was highly and strongly expressed on uterine myoma and adenomyosis. Our data suggest that MIS/AMH may be evaluated as a biological modulator or therapeutic agent on MIS/AMHRII expressing uterine myoma and adenomyosis.
Abstract
Objective We compared the expression levels of Müllerian inhibiting substance (MIS)/anti-Müllerian hormone type II receptor (AMHRII) in uterine myoma and adenomyosis to evaluate the possibility of using MIS/anti-Müllerian hormone (AMH) as a biological regulator or therapeutic agent in patients with uterine leiomyoma and adenomyosis. Methods We studied normal uterine myometrium, leiomyoma, endometrial tissue, and adenomyosis from 57 patients who underwent hysterectomy for uterine leiomyoma (22 cases) or adenomyosis (28 cases) and myomectomy for uterine myoma (7 cases). Immunohistochemical staining was used to confirm the MIS/AMHRII protein expression level in each tissue. Reverse transcription-polymerase chain reaction was performed to quantify MIS/AMHRII mRNA expression. Results The MIS/AMHRII protein was more strongly expressed in uterine myoma (frequency of MIS/AMHRII expressing cells: 51.95%±13.96%) and adenomyosis (64.65%±4.85%) tissues than that in the normal uterine myometrium (3.15%±1.69%) and endometrium (31.10%±7.19%). In the quantitative analysis of MIS/AMHRII mRNA expression, MIS/AMHRII mRNA expression levels in uterine myoma (mean density: 4.51±0.26) and adenomyosis (6.84±0.20) tissues were higher than that in normal uterine myometrial tissue (0.08±0.09) and endometrial tissue (1.63±0.06). Conclusion This study demonstrated that MIS/AMHRII was highly and strongly expressed on uterine myoma and adenomyosis. Our data suggest that MIS/AMH may be evaluated as a biological modulator or therapeutic agent on MIS/AMHRII expressing uterine myoma and adenomyosis.
참고문헌 (30)
- Rey R, "AMH", MIS: what we know already about the gene, the protein and its regulation, 2003, pp.211, 21~31
- He WW, "Developmental expression of four novel serine", threonine kinase receptors homologous to the activin, Dev Dyn, pp.1993, 196[DOI]
- TEX> in cancer therapy: volume I basic and clinical biology, "Transforming growth factor-<TEX>$\beta$<", pp.2008, MacLaughlin DT
- Kim JH, "Mullerian inhibiting substance: physiology and clinical applications", J Womens Med, 2, pp.45~47 (2009)
- Lee HB, "Expression of Mullerian Inhibiting Substance (MIS) and its receptor in female genital tract", World J Pathol, 2, pp.14~24 (2013)
- Fanchin R, "High reproducibility of serum anti-Mullerian hormone measurements suggests a multi-staged follicular secretion and strengthens its role in the assessment of ovarian follicular status", Hum Reprod, 20, pp.923~927 (2005)[DOI]
- Hudson PL, "An immunoassay to detect human mullerian inhibiting substance in males and females during normal development", J Clin Endocrinol Metab, 70, pp.16~22 (1990)[DOI]
- Lee MM, "Mullerian inhibiting substance in humans: normal levels from infancy to adulthood", J Clin Endocrinol Metab, 81, pp.571~576 (1996)
- Chin TW, "Human mullerian inhibiting substance inhibits tumor growth in vitro and in vivo", Cancer Res, 51, pp.2101~2106 (1991)
- Fuller AF Jr, "Mullerian inhibiting substance reduction of colony growth of human gynecologic cancers in a stem cell assay", Gynecol Oncol, 22, pp.135~148 (1985)[DOI]
- 김장흡, "Müllerian inhibiting substance", anti-Müllerian hormone: A novel treatment for gynecologic tumors, 2014, pp.57(05), 343~357[DOI]
- Stephen AE, "Highly purified mullerian inhibiting substance inhibits human ovarian cancer in vivo", Clin Cancer Res, 8, pp.2640~2646 (2002)
- Park SH, "Mullerian inhibiting substance inhibits an ovarian cancer cell line via b-catenin interacting protein deregulation of the Wnt signal pathway", Int J Oncol, 50, pp.1022~1028 (2017)[DOI]
- Masiakos PT, "Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS", Clin Cancer Res, 5, pp.3488~3499 (1999)
- Ha TU, "Mullerian inhibiting substance inhibits ovarian cell growth through an Rb-independent mechanism", J Biol Chem, 275, pp.37101~37109 (2000)[DOI]
- Song JY, "The expression of Mullerian inhibiting substance", anti-Mullerian hormone type II receptor protein and mRNA in benign, borderline and malignant ovarian neoplasia, 2009, pp.34, 1583~1591
- Nam SW, "Identification of large-scale characteristic genes of Mullerian inhibiting substance in human ovarian cancer cells", Int J Mol Med, 23, pp.589~596 (2009)
- Wang JJ, "Characterization of mullerian inhibiting substance binding on cervical carcinoma cells demonstrated by immunocytochemistry", Tissue Cell, 26, pp.467~476 (1994)[DOI]
- Song JY, "Expression of Mullerian inhibiting substance type II receptor and antiproliferative effects of MIS on human cervical cancer", Int J Oncol, 40, pp.2013~2021 (2012)
- Hwang SJ, "Identification of characteristic molecular signature of Mullerian inhibiting substance in human HPV-related cervical cancer cells", Int J Oncol, 39, pp.811~820 (2011)
- Barbie TU, "Mullerian Inhibiting Substance inhibits cervical cancer cell growth via a pathway involving p130 and p107", Proc Natl Acad Sci U S A, 100, pp.15601~15606 (2003)[DOI]
- Renaud EJ, "Endometrial cancer is a receptor-mediated target for Mullerian Inhibiting Substance", Proc Natl Acad Sci U S A, 102, pp.111~116 (2005)[DOI]
- Chung YJ, "Transcriptome analysis reveals that Mullerian inhibiting substance regulates signaling pathways that contribute to endometrial carcinogenesis", Int J Oncol, 46, pp.2039~2046 (2015)[DOI]
- Namkung J, "Mullerian inhibiting substance induces apoptosis of human endometrial stromal cells in endometriosis", J Clin Endocrinol Metab, 97, pp.3224~3230 (2012)[DOI]
- Parker WH, "Etiology, symptomatology, and diagnosis of uterine myomas", Fertil Steril, 87, pp.725~736 (2007)[DOI]
- Bulun SE, "Uterine fibroids", N Engl J Med, 369, pp.1344~1355 (2013)[DOI]
- Yen CF, "Molecular characteristics of the endometrium in uterine adenomyosis and its biochemical microenvironment", Reprod Sci, 24, pp.1346~1361 (2017)[DOI]
- Perez-Lopez FR, "EMAS position statement: management of uterine fibroids", Maturitas, 79, pp.106~116 (2014)[DOI]
- Vilos GA, "The management of uterine leiomyomas", J Obstet Gynaecol Can, 37, pp.157~178 (2015)[DOI]
- Farquhar C, "Medical and surgical management of adenomyosis", Best Pract Res Clin Obstet Gynaecol, 20, pp.603~616 (2006)[DOI]